Clinical Trials Directory

Trials / Terminated

TerminatedNCT03670069

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

A Pilot Study Examining the Impact of the Jak1 Inhibitor Itacitinib on the Sarcoma Tumor Immune Microenvironment

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
27 (actual)
Sponsor
Fred Hutchinson Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This pilot phase I trial studies how well itacitinib works in treating patients with sarcomas that do not respond to treatment (refractory) and have spread to other parts of the body (advanced/metastatic). Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed description

OUTLINE: Patients receive itacitinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 7 and 30 days, every 12 weeks from baseline for up to 1 year, and then every 6 months thereafter.

Conditions

Interventions

TypeNameDescription
DRUGItacitinibGiven PO
OTHERLaboratory Biomarker AnalysisCorrelative studies

Timeline

Start date
2019-09-30
Primary completion
2023-03-04
Completion
2024-05-06
First posted
2018-09-13
Last updated
2024-05-08

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03670069. Inclusion in this directory is not an endorsement.

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas (NCT03670069) · Clinical Trials Directory